Skip to content

Treatment of Periodontal Intra-bony Defects With a Volume Stable Collagen Matrix or Deproteinized Bovine Bone Mineral With 10% Collagen

Treatment of Periodontal Intra-bony Defects With a Volume Stable Collagen Matrix or Deproteinized Bovine Bone Mineral With 10% Collagen. A 12-month Multi-center Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06676826
Enrollment
80
Registered
2024-11-06
Start date
2025-09-01
Completion date
2027-12-30
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases

Brief summary

To compare the healing of intrabony periodontal defects treated with either open flap debridement and a volume-stable collagen matrix (VCMX) or a deproteinized bovine bone mineral with 10% collagen. The results will shed light on the clinical potential of VCMX in regenerative periodontal surgery and help to develop new treatment strategies.

Interventions

DEVICEInfrabony defects will be filled with a volume-stable collagen matrix (VCMX)

Infrabony defects will be filled with a volume-stable collagen matrix

DEVICEInfrabony defects will be filled treated with a deproteinized bovine bone mineral with 10% collagen

Infrabony defects will be filled with with a deproteinized bovine bone mineral with 10% collagen

Sponsors

University of Bern
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients with localized or generalized periodontitis Stage III and Stage IV, Grade A-B-C * Males and females * Age at least 18 years and older * Presence of interdental intra-bony defects (I, II and III walls) in either the maxilla or the mandible with a PD ≥ 6 mm * Defects with an intra-bony component > 3 mm for both groups * Intra-bony defect located only at one aspect (mesial or distal) * Presence of at least 2 mm of keratinized soft tissue.

Exclusion criteria

* Patients with systemic disease that could interfere with periodontal wound healing * Prolonged antibiotic treatment or anti-inflammatory treatment within 4 weeks prior to surgery * Pregnant or lactating * Smokers with > 10 cig./day * Patients with FMPS and FMBS > 25 % after completion of non-surgical periodontal therapy * Multi-rooted teeth with furcation involvement * Third molars * Teeth with circumferential defects * Interdental craters * Written Informed Consent

Design outcomes

Primary

MeasureTime frameDescription
Clinical attachment level (CAL) change12 monthsClinical attachment level (CAL) change in mm: the distance from the cemento-enamel junction to the bottom of the clinical periodontal pocket is being measured

Secondary

MeasureTime frameDescription
Bleeding on probing (BoP)Baseline, 12 monthsAssessment of number of bleeding spots (percentage 0-100%) upon gentle probing of PPD at each test and control tooth site
Pocket probing depth (PPD)Baseline, 12 monthsWith a periodontal probe with mm markings, the distance between the gingival margin and the bottom of the pocket will be measured
Microbiological analysis1, 3, 12 weeksQuantification of the concentration of host-derived biomarkers (interleukin-1beta (IL-1b), IL-10, matrix-metalloproteinase- 8(MMP-8)) and periodontal bacterial species by means of gingival crevicular fluid and the biofilm sampling

Countries

Switzerland

Contacts

Primary ContactAlexandra Stähli, MD
alexandra.staehli@unibe.ch+41316840600
Backup ContactAndrea Roccuzzo, PhD
andrea.roccuzzo@unibe.ch+41316840600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026